See also this year's filing and all EDGAR filings for this company.
PDF Report 0001737523_2026_Bionexus_Gene_Lab_Corp.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Liabilities', 'missing_ratio': 0.15488337275009773, 'aggregate_val': 637856, 'exp_sum': 754755, 'exp_to_value': {'LongTermLiabilities': 116899, 'LiabilitiesCurrent': 520957, 'remainder_Liabilities': 116899}} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.29134529591026304, 'aggregate_val': 9252784, 'exp_sum': 13056830, 'exp_to_value': {'IntangibleAssets': 0, 'AssetsNonCurrent': 3804046, 'AssetsCurrent': 5448738, 'PropertyPlantAndEquipment': 1598769, 'remainder_Assets': 2205277}} |
Graph
Absolute values for 0001737523, Bionexus Gene Lab Corp
| xvar | xval | |
|---|---|---|
| 0 | IntangibleAssets | 0 |
| 1 | AssetsNonCurrent | 3,804,046 |
| 2 | AssetsCurrent | 5,448,738 |
| 3 | PropertyPlantAndEquipment | 1,598,769 |
| 4 | remainder_Assets | -1,598,769 |
| 5 | LongTermLiabilities | 116,899 |
| 6 | LiabilitiesCurrent | 520,957 |
| 7 | remainder_Liabilities | 0 |
| 8 | LaborExpense | 0 |
| 9 | CostOfGoodsAndServicesSold | 6,339,694 |
| 10 | GeneralAndAdministrativeExpense | 1,535,452 |
| 11 | GoodwillImpairmentLoss | 0 |
| 12 | OperatingCostsAndExpenses | 0 |
| 13 | DepreciationDepletionAndAmortization | 0 |
| 14 | SellingAndMarketingExpense | 1,736,331 |
| 15 | ResearchAndDevelopmentExpense | 50,670 |
| 16 | remainder_Expenses | 1,179,488 |
| 17 | remainder_Revenues | 7,857,028 |
| 18 | remainder_NetIncome | 0 |
| 19 | remainder_ComprehensiveNetIncome | 434,251 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 9,252,784 |
| 1 | Liabilities | 637,856 |
| 2 | Expenses | 10,841,635 |
| 3 | Revenues | 7,857,028 |
| 4 | StockholdersEquity | 8,614,928 |
| 5 | NetIncome | -2,984,607 |
| 6 | ComprehensiveNetIncome | -2,550,356 |
| 7 | BaseVar | 14,511,777 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 2.01 |
| 9 | EconomicCapitalRatio | 2.39 |